Medicus Pharma Says INAD File No.013880 Received Minor Use In Major Species Designation From FDA For Its Dissolvable D-MNA To Treat External Squamous Cell Carcinoma In Horses

Benzinga · Dec 12 20:47

The company received a notification from the FDA on December 9th 2024.

MUMS is a status similar to Orphan Drug status for human drugs. It entitles the company to an extended 7-year period of exclusive marketing following approval or conditional approval, provided that the company meets all requirements for maintaining the designation.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Medicus Pharma Says INAD File No.013880 Received Minor Use In Major Species Designation From FDA For Its Dissolvable D-MNA To Treat External Squamous Cell Carcinoma In Horses

Risk Disclaimer